دورية أكاديمية
Therapeutic potential of acarbose in ameliorating the metabolic and endocrinological complications of polycystic ovarian syndrome: a review.
| العنوان: | Therapeutic potential of acarbose in ameliorating the metabolic and endocrinological complications of polycystic ovarian syndrome: a review. |
|---|---|
| المؤلفون: | Andavar M; SRM College of Pharmacy, Department of Pharmacy Practice, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India., Kamaraj R; SRM College of Pharmacy, Department of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India., Vijayakumar TM; SRM College of Pharmacy, Department of Pharmacy Practice, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India., Murugesan A; SRM Medical College Hospital and Research Centre, Department of Obstetrics and Gynaecology, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India. |
| المصدر: | Current medical research and opinion [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1123-1135. Date of Electronic Publication: 2024 Jun 09. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare Original Publication: London, M. D. Promotions, ltd. |
| مواضيع طبية MeSH: | Acarbose*/therapeutic use , Polycystic Ovary Syndrome*/drug therapy , Polycystic Ovary Syndrome*/complications, Female ; Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/adverse effects ; Insulin Resistance |
| مستخلص: | Polycystic ovarian syndrome is a perplexed condition addressing endocrinal, cardiometabolic and gynaecological issues. It affects women of adolescent age and is drastically increasing in the Indo-Asian ethnicity over the recent years. According to Rotterdam criteria, PCOS is characterized by clinical or biochemical excess androgen and polycystic ovarian morphology; however, it has been established in the recent years that PCOS exacerbates to further serious metabolic conditions on the long term. This is a narrative literature review and not systematic review and is based on PubMed searches with relevant keywords "Polycystic ovarian syndrome AND acarbose OR metformin OR myoinositol; PCOS AND metabolic syndrome OR cardiovascular disease OR menstrual irregularity OR infertility OR chronic anovulation OR clinical hyperandrogenism" used in the title and are limited to articles published in English language with no time limits. A prominent aspect of PCOS is hyperandrogenaemia and hyperinsulinemia. About 50-70% of afflicted women have compensatory hyperinsulinemia and close to one tierce suffer from anovulation and infertility. Insulin resistance leads to metabolic complications and works with luteinizing hormone in increasing the ovarian androgen production. This excess androgen leads to clinical manifestations, irregular menstrual cycles and infertility. There isn't an entire cure, only the symptomatic clinical factors are considered rather than focusing on the underlying long-term complications. Therefore, the article focuses on a potent alpha glucosidase inhibitor, acarbose which suppresses the post meal glucose and insulin by delaying the absorption of complex carbs. It exhibits cardio-metabolic and hormonal benefits and is well tolerable in the south asian population. This review highlights the safety, effectiveness of acarbose in ameliorating the long-term complications of PCOS. |
| فهرسة مساهمة: | Keywords: acarbose; hyperandrogenemia; hyperinsulinemia; metabolic syndrome; polycystic ovarian syndrome |
| المشرفين على المادة: | T58MSI464G (Acarbose) 0 (Hypoglycemic Agents) |
| تواريخ الأحداث: | Date Created: 20240521 Date Completed: 20240705 Latest Revision: 20240708 |
| رمز التحديث: | 20240708 |
| DOI: | 10.1080/03007995.2024.2358237 |
| PMID: | 38771729 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher كن أول من يترك تعليقا!